文献速递神经肿瘤

IDH突变型4级星形细胞瘤:原发与继发患者的临床、病理及生存特征比较

IDH-mutant grade 4 astrocytoma: a comparison integrating the clinical, pathological, and survival features between primary and secondary patients.
PubMed 文献 · J Neurosurg · 2023-06-30

研究比较了103例原发IDH突变型4级星形细胞瘤(pAIDHmut/G4)与108例继发IDH突变型4级星形细胞瘤(sAIDHmut/G4)的临床、病理及生存特征。sAIDHmut/G4患者中位总生存期(11.8 vs 34.2个月,HR 2.69,95%CI 1.367-5.306,p=0.004)和无进展生存期(8.5 vs 24.3个月,HR 2.83,95%CI 1.532-5.235,p=0.001)均显著短于pAIDHmut/G4患者。两组独立预后因素不同,为AIDHmut/G4的治疗决策提供了参考。

要点

  • sAIDHmut/G4较pAIDHmut/G4中位OS(11.8 vs 34.2个月,HR 2.69)和PFS(8.5 vs 24.3个月,HR 2.83)均显著缩短。
  • sAIDHmut/G4中切除状态和化疗是OS和PFS的独立预后因素。
  • pAIDHmut/G4中低级别胶质瘤成分、切除状态和MGMT启动子甲基化是独立预后因素。

核心结论

  • sAIDHmut/G4与pAIDHmut/G4具有不同的临床特征、生存期和风险因素,为AIDHmut/G4的治疗决策提供了参考。

研究设计与样本

  • 回顾性比较研究,从871例有IDH突变数据的4级星形细胞瘤中纳入698例原发肿瘤(80.1%)和173例继发肿瘤(19.9%)。
  • 原发肿瘤中103例(14.8%)为pAIDHmut/G4,继发肿瘤中108例(62.4%)为sAIDHmut/G4,比较两组临床、病理和生存特征。
  • 采用多因素分析识别预后因素。

主要发现

  • sAIDHmut/G4患者中位OS为11.8个月 vs pAIDHmut/G4的34.2个月(HR 2.69,95%CI 1.367-5.306,p=0.004),差异显著。
  • sAIDHmut/G4患者中位PFS为8.5个月 vs pAIDHmut/G4的24.3个月(HR 2.83,95%CI 1.532-5.235,p=0.001),差异显著。
  • sAIDHmut/G4中切除状态和化疗是OS和PFS的独立预后因素。
  • pAIDHmut/G4中低级别胶质瘤成分、切除状态和MGMT启动子甲基化是独立预后因素。
  • 低级别胶质瘤阶段的治疗策略未影响sAIDHmut/G4患者的生存,但诊断低级别胶质瘤时未接受放疗或化疗的患者进展为sAIDHmut/G4后从放疗或化疗中获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: IDH-mutant grade 4 astrocytomas (AIDHmut/G4) are divided into primary de novo (pAIDHmut/G4) and secondary with a history of prior lower-grade gliomas (LGGs; sAIDHmut/G4). The mutational spectrum and DNA methylation patterns are homogeneous within de novo pAIDHmut/G4 and evolved sAIDHmut/G4, but the two groups have different diagnoses, management, and outcomes. This study sought to systematically compare the clinical, pathological, and survival characteristics between them. METHODS: Of the 871 grade 4 astrocytomas with data for IDH mutation, 698 (80.1%) were primary and 173 (19.9%) were secondary. Of the 698 primary tumors, 103 (14.8%) were pAIDHmut/G4, and of the 173 secondary tumors, 108 (62.4%) were sAIDHmut/G4. Clinical, pathological, and survival features were compared between pAIDHmut/G4 and sAIDHmut/G4. Multivariate analyses were performed to identify prognostic factors. RESULTS: Patients with sAIDHmut/G4 had significantly shorter median overall survival (OS; 11.8 vs 34.2 months, hazard ratio [HR] 2.69, 95% confidence interval [CI] 1.367-5.306, p = 0.004) and progression-free survival (PFS; 8.5 vs 24.3 months, HR 2.83, 95% CI 1.532-5.235, p = 0.001) than patients with pAIDHmut/G4. In patients with sAIDHmut/G4, resection status and chemotherapy were independent prognostic factors for OS and PFS; in patients with pAIDHmut/G4, LGG component, resection status, and O6-methylguanine DNA methyltransferase promoter methylation were independent prognostic factors. The therapeutic strategies of LGGs did not influence survival of patients with sAIDHmut/G4, but patients who had not received radiotherapy or chemotherapy when they were diagnosed with LGGs were found to benefit from radiotherapy or chemotherapy when they progressed to sAIDHmut/G4. CONCLUSIONS: The different clinical characteristics, survival, and risk factors between sAIDHmut/G4 and pAIDHmut/G4 provide a reference to guide treatment decisions in AIDHmut/G4.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Liu Y, Gao D, Chen H, et al. IDH-mutant grade 4 astrocytoma: a comparison integrating the clinical, pathological, and survival features between primary and secondary patients. J Neurosurg. 2023. PMID: 37410628. doi:10.3171/2023.5.JNS222658

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。